api-3

FAPI-34, a fibroblast-activating protein (FAP) inhibitor, boasts advantageous pharmacokinetic and biochemical attributes.

SKQ1, also known as Visomitin or plastoquinonyl decyltriphenyl phosphonium (PDTP), is a potent mitochondrial-targeted antioxidant. As the active pharmaceutical ingredient (API) in Visomitin eye drops, SKQ1 exhibits various biomedical activities: (1) prevents impairment of long-term potentiation in rat hippocampal slices caused by amyloid β-protein; (2) reverses aging-related biomarkers in rats; (3) slows age-related degenerative changes in the retinas and choroid of Wistar and OXYS rats; (4) extends the lifespan of male rodents in LP or SPF conditions. SKQ1 can penetrate cell membranes and is proposed for use in anti-aging therapies. Clinical trials for SKQ1 are currently underway in Russia to treat glaucoma. For convenience, SKQ1 is provided as an ethanol-water (1:1, v v) solution at a concentration of 200 mg mL.

Motexafin gadolinium, also known as PCI 0120, is a synthetic metallotexaphyrin with radiosensitizing and chemosensitizing properties. Motexafin gadolinium accumulates in tumor cells preferentially due to their increased rates of metabolism, generating rea